COVID-19 Coronavirus

Merck & Co Inc (NYSE: MRK) Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19.  The Phase 3 MOVe-AHEAD trial evaluated people who did not have COVID-19 at...

eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced top-line results from its Phase 1b clinical trial of zotatifin for COVID-19 infection. The data demonstrated favorable safety results and positive trends in several measures of antiviral activity.  eFFECTOR also presented...

A High Court battle between Pfizer Inc (NYSE: PFE), its partner BioNTech SE (NASDAQ: BNTX) locked in a dispute with the rival COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) over patents for vaccine technology is set to be heard in London next year. In August,...

Moderna Inc's (NASDAQ: MRNA) CEO, Stéphane Bancel, will testify next month on its plans to raise the price of its COVID-19 vaccine in front of the Senate. In January, Senator Bernie Sanders had written to Bancel to refrain from shooting up the prices of the COVID-19 vaccine after...

Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  Vir will continue its ongoing efforts to discover, develop and advance COVID-19 solutions and other potential coronavirus outbreaks, ...

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.  The data exhibited that among predominantly vaccinated participants with COVID...

According to some researchers, Merck & Co’s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. Mutations linked to Merck’s COVID-19 oral treatment Lagevrio (Molnupiravir) have been identified in viral samples taken from several...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) agreed to acquire all of the assets of Healion Bio Inc (Healion), including its entire portfolio of next-generation antiviral technology assets.  Healion's drug portfolio includes a class of broad-spectrum small-molecule...

Biophytis SA (NASDAQ: BPTS) released the final results from its phase 2-3 COVA study evaluating Sarconeos (BIO101) for COVID-19-related respiratory failure.  Biophytis announces final results following the reintegration of data from 54 patients, among 233 patients treated, that...

The Biden administration will allow the ongoing Covid-19 emergency declarations to end on May 11, the White House announced on Monday, as the U.S. shifts away from responding to the pandemic as a national crisis and instead manage the virus more like a seasonal respiratory disease. The...

CureVac N.V. (NASDAQ: CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK plc (NYSE: GSK). The newly reported data focus on older adult age groups. COVID-19 Program Newly reported...

Axcella Health Inc (NASDAQ: AXLA) announced a regulatory path to the registration of AXA1125 for Long COVID Fatigue. The company received regulatory guidance from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA), supporting a single trial that could serve as the...

BiondVax Pharmaceuticals Ltd (NYSE: BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.  The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb...

The FDA is considering a significant shift in the U.S.'s COVID-19 vaccine strategy to simplify vaccination against COVID-19. Citing an undisclosed federal official, NPR wrote the agency might look at an approach similar to that used for the flu vaccine, with annual updates to match...

Israel health ministry official said Isreal had not identified any evidence linking strokes to an updated coronavirus vaccine by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). "We have not turned up such a finding, even after we went back and rechecked all our data...